These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
275 related articles for article (PubMed ID: 29683099)
61. Pamidronate inhibits antiapoptotic bcl-2 expression through inhibition of the mevalonate pathway in prostate cancer PC-3 cells. Iguchi K; Tatsuda Y; Usui S; Hirano K Eur J Pharmacol; 2010 Sep; 641(1):35-40. PubMed ID: 20519142 [TBL] [Abstract][Full Text] [Related]
62. Bisphosphonates: mode of action and pharmacology. Russell RG Pediatrics; 2007 Mar; 119 Suppl 2():S150-62. PubMed ID: 17332236 [TBL] [Abstract][Full Text] [Related]
63. Could drugs inhibiting the mevalonate pathway also target cancer stem cells? Likus W; Siemianowicz K; Bieńk K; Pakuła M; Pathak H; Dutta C; Wang Q; Shojaei S; Assaraf YG; Ghavami S; Cieślar-Pobuda A; Łos MJ Drug Resist Updat; 2016 Mar; 25():13-25. PubMed ID: 27155373 [TBL] [Abstract][Full Text] [Related]
64. [Prevention of osteoporosis by foods and dietary supplements. Hesperidin and bone metabolism]. Uehara M Clin Calcium; 2006 Oct; 16(10):1669-76. PubMed ID: 17012820 [TBL] [Abstract][Full Text] [Related]
65. Osteoporosis: From Molecular Mechanisms to Therapies 2.0. Tang CH Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33126410 [TBL] [Abstract][Full Text] [Related]
66. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603 [TBL] [Abstract][Full Text] [Related]
67. Skeletal effects of statins. Yaturu S Endocr Pract; 2003; 9(4):315-20. PubMed ID: 14561578 [TBL] [Abstract][Full Text] [Related]
68. Gamma-tocotrienol reverses multidrug resistance of breast cancer cells with a mechanism distinct from that of atorvastatin. Ding Y; Peng Y; Deng L; Fan J; Huang B J Steroid Biochem Mol Biol; 2017 Mar; 167():67-77. PubMed ID: 27864002 [TBL] [Abstract][Full Text] [Related]
69. Parkinson's disease and osteoporosis. van den Bos F; Speelman AD; Samson M; Munneke M; Bloem BR; Verhaar HJ Age Ageing; 2013 Mar; 42(2):156-62. PubMed ID: 23132148 [TBL] [Abstract][Full Text] [Related]
70. Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins. Göbel A; Browne AJ; Thiele S; Rauner M; Hofbauer LC; Rachner TD Breast Cancer Res Treat; 2015 Dec; 154(3):623-31. PubMed ID: 26515701 [TBL] [Abstract][Full Text] [Related]
71. Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton. Rogers MJ; Mönkkönen J; Munoz MA Bone; 2020 Oct; 139():115493. PubMed ID: 32569873 [TBL] [Abstract][Full Text] [Related]
72. [Pharmacological profile and clinical efficacy of minodronic acid hydrate as a new therapeutic agent for osteoporosis]. Tanaka M; Mori H; Shimizu K; Toshiyuki ; Matsuoka ; Yamamotoya H; Minamide T; Mori M; Nozaki K; Usui T; Shimokawa K; Suzuki H; Aoyama K; Kimoto A; Sasamata M; Miyata K Nihon Yakurigaku Zasshi; 2009 Sep; 134(3):149-57. PubMed ID: 19749488 [No Abstract] [Full Text] [Related]
73. The biological effects of tocotrienol on bone: a review on evidence from rodent models. Chin KY; Ima-Nirwana S Drug Des Devel Ther; 2015; 9():2049-61. PubMed ID: 25897211 [TBL] [Abstract][Full Text] [Related]
74. Age-related changes in marmoset trabecular and cortical bone and response to alendronate therapy resemble human bone physiology and architecture. Bagi CM; Volberg M; Moalli M; Shen V; Olson E; Hanson N; Berryman E; Andresen CJ Anat Rec (Hoboken); 2007 Aug; 290(8):1005-16. PubMed ID: 17610276 [TBL] [Abstract][Full Text] [Related]
75. Farnesyl acetate, a derivative of an isoprenoid of the mevalonate pathway, inhibits DNA replication in hamster and human cells. Meigs TE; Sherwood SW; Simoni RD Exp Cell Res; 1995 Aug; 219(2):461-70. PubMed ID: 7641798 [TBL] [Abstract][Full Text] [Related]
76. Mevalonate Biosynthesis Intermediates Are Key Regulators of Innate Immunity in Bovine Endometritis. Healey GD; Collier C; Griffin S; Schuberth HJ; Sandra O; Smith DG; Mahan S; Dieuzy-Labaye I; Sheldon IM J Immunol; 2016 Jan; 196(2):823-31. PubMed ID: 26673142 [TBL] [Abstract][Full Text] [Related]
77. Effects of ibandronate on bone quality: preclinical studies. Bauss F; Dempster DW Bone; 2007 Feb; 40(2):265-73. PubMed ID: 16996333 [TBL] [Abstract][Full Text] [Related]
78. Influence of HMG-CoA reductase inhibitors on leptin-induced endothelial cell proliferation, migration, and capillary-like tube formation. Burgazli KM; Stein NI; Mericliler M; Parahuleva M; Erdogan A Postgrad Med; 2014 May; 126(3):231-8. PubMed ID: 24918807 [TBL] [Abstract][Full Text] [Related]
79. Molecular mechanisms of action of bisphosphonates: current status. Roelofs AJ; Thompson K; Gordon S; Rogers MJ Clin Cancer Res; 2006 Oct; 12(20 Pt 2):6222s-6230s. PubMed ID: 17062705 [TBL] [Abstract][Full Text] [Related]
80. The balance between induction and inhibition of mevalonate pathway regulates cancer suppression by statins: A review of molecular mechanisms. Ahmadi Y; Ghorbanihaghjo A; Argani H Chem Biol Interact; 2017 Aug; 273():273-285. PubMed ID: 28668359 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]